Ind-Swift Laboratories Ltd (INDSWFTLAB) — shareholding pattern, promoter holding, financials and share price

About Ind-Swift Laboratories Ltd (INDSWFTLAB)

Ind-Swift Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as INDSWFTLAB and on the BSE under scrip code 532305. Its ISIN is INE915B01019.

Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals [1]

Ind-Swift Laboratories Ltd is a pharmaceutical manufacturer repositioned as a pure‑play Finished Dosage Formulations (FDF) company focused on exports, contract manufacturing (CDMO/CMO) and domestic branded/ethical therapies, operating two accredited manufacturing sites (Derabassi EOU and Samba) and an R&D centre supporting regulated‑market dossiers and tech transfers.

The company completed a strategic reset by divesting its capital‑intensive API & CRAMS business for ₹1,650 Cr, repaying all external debt and emerging as a net‑debt‑free formulations platform with a retained 7.8% stake in the buyer, materially improving balance sheet flexibility for growth investments.

Listed peers in Pharmaceuticals: Indoco Remedies Ltd, Beta Drugs Ltd, Venus Remedies Ltd, NGL Fine Chem Ltd, Sakar Healthcare Ltd, Hester Biosciences Ltd.

Valuation & Returns

10 Jul 2026

At ₹246.4 a share on 10 Jul 2026, Ind-Swift Laboratories Ltd (INDSWFTLAB) was valued at a price-to-earnings ratio of 51.86x against an industry P/E of 36.41x and a price-to-book of 1.83x on a book value of ₹134.89 per share as of Mar 2025. Solomo computes return on equity of 3.52% and return on capital employed of 4.16% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
51.86x
Industry P/E
36.41x
P/B
1.83x
EPS (TTM)
₹4.75
Book value / share
₹134.89
ROE
3.52%
ROCE
4.16%
ROA
2.87%
Debt / equity
0.03x
Dividend yield
0%
EBITDA margin
12.95%
52-week range
₹87 – ₹247.8

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Ind-Swift Laboratories Ltd (INDSWFTLAB) reported revenue of ₹641 crore, net profit of ₹41 crore and earnings per share of ₹4.77. That compares with revenue of ₹562 crore and net profit of ₹250 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹170 crore and net profit ₹15 crore (consolidated).

Consolidated annual results for Ind-Swift Laboratories Ltd (INDSWFTLAB), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)1,0391,2071,281562641
Net profit (₹ cr)-24842125041
EPS (₹)-0.368.0671.2441.324.77
Compound annual growth for Ind-Swift Laboratories Ltd (INDSWFTLAB). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth-1.99%-6.07%-17.76%-56.15%
Profit growth----40.56%
Stock price CAGR20%15%41%122%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 42.93% of Ind-Swift Laboratories Ltd (INDSWFTLAB) (down 0.06 pp QoQ), foreign institutional investors (FII) hold 10.7% and domestic institutional investors (DII) hold 0.17%. Market capitalisation was ₹2,143 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2001.

Largest disclosed public shareholders in Jun 2026: ZEAL GLOBAL OPPORTUNITIES FUND 4.62%, NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE 2.96%, PANCHKULA FINVEST PRIVATE LIMITED 2.41%, ASHOKKUMAR CHANDAK 2.21%, ZAKI ABBAS NASSER 2.11%, PRANAV JONEJA 1.44%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202642.93%-10.7%0.17%57.07%
Mar 202642.99%-13.88%0%57.01%
Dec 202539.5%-14.33%0.68%60.5%
Sep 202539.5%-14.8%0.68%60.5%
Jun 202540.94%-4.27%0.91%59.06%
Mar 202540.94%-3.07%0.91%59.06%
Dec 202442%-0.46%0.94%58%
Sep 202442%-0.65%0.94%58%
Every quarter since Jun 2001 Filing data, not investment advice.